Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $103.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective increased by Cantor Fitzgerald from $96.00 to $103.00 in a research note published on Thursday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently commented on RARE. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Monday, August 10th. Wedbush reduced their target price on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Barclays decreased their price target on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a research note on Wednesday, April 29th. Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. Finally, Guggenheim dropped their price objective on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $58.89.

Ultragenyx Pharmaceutical Price Performance

RARE opened at $25.83 on Thursday. Ultragenyx Pharmaceutical has a 12 month low of $18.29 and a 12 month high of $39.89. The stock has a market capitalization of $2.55 billion, a price-to-earnings ratio of -4.42 and a beta of 0.35. The business has a fifty day moving average price of $28.58 and a 200 day moving average price of $24.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($1.22) by $0.32. The company had revenue of $214.00 million for the quarter, compared to the consensus estimate of $183.08 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.Ultragenyx Pharmaceutical’s revenue was up 28.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.17) EPS. On average, research analysts anticipate that Ultragenyx Pharmaceutical will post -4.03 earnings per share for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 4,653 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $23.77, for a total transaction of $110,601.81. Following the sale, the chief financial officer owned 105,689 shares of the company’s stock, valued at approximately $2,512,227.53. This trade represents a 4.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Karah Herdman Parschauer sold 1,899 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $24.62, for a total value of $46,753.38. Following the sale, the executive vice president owned 94,462 shares of the company’s stock, valued at approximately $2,325,654.44. The trade was a 1.97% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 8,552 shares of company stock valued at $207,455. 5.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several hedge funds have recently added to or reduced their stakes in the stock. denkapparat Operations GmbH acquired a new stake in Ultragenyx Pharmaceutical during the second quarter worth approximately $230,000. Nykredit A S acquired a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at $154,000. Palo Alto Investors LP acquired a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at $19,916,968,000. Jefferies Financial Group Inc. purchased a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at $31,040,000. Finally, Capstone Investment Advisors LLC purchased a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at $549,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: The FDA granted accelerated approval to Genglycos (pariglasgene brecaparvovec), Ultragenyx’s gene therapy for glycogen storage disease type Ia (GSDIa). It is the first FDA-approved treatment designed to address the underlying cause of the rare metabolic disorder, potentially expanding the company’s commercial opportunity and strengthening its gene-therapy platform. Ultragenyx Announces FDA Approval of Genglycos
• Positive Sentiment: Analysts raised their valuations following the approval. Cantor Fitzgerald increased its price target to $103 from $96 and maintained an “overweight” rating; Canaccord raised its target to $83 from $81 with a “buy” rating; Morgan Stanley lifted its target to $74 from $67 and maintained “overweight”; Citi raised its target to $58 from $45 with a “buy” rating; and Wells Fargo increased its target to $46 from $45 while retaining “overweight.” Ultragenyx FDA approval coverage
• Positive Sentiment: Wells Fargo described the gene-therapy launch as a potential long-term revenue tailwind, suggesting Genglycos could create a more durable growth stream for RARE if adoption and reimbursement develop as expected. Wells Fargo Genglycos analysis
• Neutral Sentiment: Despite the regulatory progress, investors still need evidence that Ultragenyx can convert approval into sustainable profitability. The company remains loss-making, making the pace of commercialization, revenue growth and cash generation important tests for the stock. Ultragenyx profitability analysis

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.